Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 7Phase 1/2 7Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Patient Preference 1

Interventions

Imatinib Mesylate 28nilotinib 21Cytarabine 21Methotrexate 16Hydroxyurea 15Cyclophosphamide 15Busulfan 15Peripheral Blood Stem Cell Transplantation 13ruxolitinib 11Etoposide 11Whole-Body Irradiation 10fludarabine phosphate 9fludarabine 9Tacrolimus 9Mycophenolic Acid 9Daunorubicin 9Idarubicin 8Radiotherapy 7Mitoxantrone 7Interferon-alpha 7Cyclosporine 6peginterferon alfa-2a 5bosutinib 5asciminib 5Melphalan 5Azacitidine 5merphos 4luspatercept 4Thioguanine 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × decitabine and cedazuridine drug combination × Myeloid × Clear all
NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Astex Pharmaceuticals, Inc.

Phase 3 Completed
227 enrolled 37 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡